Last reviewed · How we verify
Fluticasone Propionate 500 microgram dose
Fluticasone Propionate 500 microgram dose is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | Fluticasone Propionate 500 microgram dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Propionate 500 microgram dose CI brief — competitive landscape report
- Fluticasone Propionate 500 microgram dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Fluticasone Propionate 500 microgram dose
What is Fluticasone Propionate 500 microgram dose?
Fluticasone Propionate 500 microgram dose is a Small molecule drug developed by GlaxoSmithKline.
Who makes Fluticasone Propionate 500 microgram dose?
Fluticasone Propionate 500 microgram dose is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Fluticasone Propionate 500 microgram dose in?
Fluticasone Propionate 500 microgram dose is in Phase 1.